Presbia PLC announced that it has scheduled the remaining treatments for completing the second stage enrollment of its U.S. Food and Drug Administration (FDA) pivotal study, a significant milestone in the FDA approval process of its Presbia Flexivue Microlens. The final surgeries will take place the week of September 7, 2015. The Presbia Flexivue Microlens is a revolutionary optical lens implant for treating presbyopia, the age-related loss of near vision, and has been commercially available in the European Union and other countries around the world where it has obtained regulatory approval.

In February, Presbia received FDA approval to commence the second stage pivotal study of its Microlens, which required enrollment of 337 qualified subjects. As the study ramped-up, the majority of the patients were enrolled and treated in less than five months, meeting Presbia's target to complete the required enrollment by the end of the third quarter.